Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms

Clinical guidelines for breast cancer treatment differ in their selection of patients at a high risk of recurrence who are eligible to receive adjuvant systemic treatment (AST). The 70-gene signature is a molecular tool to better guide AST decisions. The aim of this study was to evaluate whether add...

Descripción completa

Detalles Bibliográficos
Autores principales: Drukker, C. A., Nijenhuis, M. V., Bueno-de-Mesquita, J. M., Retèl, V. P., van Harten, W. H., van Tinteren, H., Wesseling, J., Schmidt, M. K., van’t Veer, L. J., Sonke, G. S., Rutgers, E. J. T., van de Vijver, M. J., Linn, S. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031388/
https://www.ncbi.nlm.nih.gov/pubmed/24760482
http://dx.doi.org/10.1007/s10549-014-2954-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031388/
https://www.ncbi.nlm.nih.gov/pubmed/24760482
http://dx.doi.org/10.1007/s10549-014-2954-2

Ejemplares similares